Phibro Animal Health Corp
NASDAQ:PAHC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.53
45.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Phibro Animal Health Corp
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 1,725 full-time employees. The company went IPO on 2014-04-11. The firm operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The firm develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The firm sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The firm's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 1,725 full-time employees. The company went IPO on 2014-04-11. The firm operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The firm develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The firm sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The firm's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
Animal Health Surge: Animal Health sales jumped 55%, with adjusted EBITDA for the segment up 85%, driven by the integration of the Zoetis Medicated Feed Additive (MFA) portfolio and strong demand across categories.
Guidance Raised: Full-year guidance for adjusted EBITDA and adjusted net income was raised, reflecting a strong start to the year and better-than-expected margin performance. Revenue guidance was kept unchanged.
MFA Strength: Medicated Feed Additives led growth with an 81% increase, and the legacy MFA business also grew by 6%; management noted growth is volume-driven but expects some price impact going forward.
Margin Performance: Margins improved due to favorable product mix, especially from higher-margin vaccines and nutritional specialties, but management expects some margin moderation for the rest of the year.
Companion Animal Expansion: The launch of Restoris, a dental gel for dogs, and the licensing of a new therapeutic compound signal a growing focus on the companion animal segment.
Cash & Leverage: Free cash flow for the trailing 12 months was $34 million, with net leverage at 2.9x and $85 million in cash and equivalents.
End Market Demand: Strong global livestock and protein demand, with positive trends in animal-based protein consumption and sector profitability, underpin business performance.